Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2006 2
2008 6
2009 2
2010 1
2011 2
2012 5
2013 4
2014 3
2015 2
2016 1
2020 1
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.
Gausi K, Mugerwa H, Siccardi M, Montanha MC, Lamorde M, Wiesner L, D'Avolio A, McIlleron H, Wilkins E, De Nicolò A, Maartens G, Khoo S, Kityo C, Denti P, Waitt C. Gausi K, et al. Among authors: wilkins e. Clin Infect Dis. 2024 May 15;78(5):1246-1255. doi: 10.1093/cid/ciad700. Clin Infect Dis. 2024. PMID: 37982585 Free PMC article.
Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals.
Babiker ZO, Douthwaite ST, Collier LE, Pennell A, Uriel AJ, Wilkins E. Babiker ZO, et al. Among authors: wilkins e. J Int Assoc Provid AIDS Care. 2013 Jan-Feb;12(1):12-4. doi: 10.1177/1545109712462454. Epub 2012 Oct 16. J Int Assoc Provid AIDS Care. 2013. PMID: 23076664 Free article.
Predictors of renal outcome in HIV-associated nephropathy.
Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, Johnson L, Fisher M, Holt SG, Bhagani S, Frankel AH, Wilkins E, Ainsworth JG, Larbalestier N, Macallan DC, Banerjee D, Baily G, Thuraisingham RC, Donohoe P, Hendry BM, Hilton RM, Edwards SG, Hangartner R, Howie AJ, Connolly JO, Easterbrook PJ. Post FA, et al. Among authors: wilkins e. Clin Infect Dis. 2008 Apr 15;46(8):1282-9. doi: 10.1086/529385. Clin Infect Dis. 2008. PMID: 18444868
Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.
Stöhr W, Dunn DT, Arenas-Pinto A, Orkin C, Clarke A, Williams I, Johnson M, Beeching NJ, Wilkins E, Sanders K, Paton NI; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team. Stöhr W, et al. Among authors: wilkins e. AIDS. 2016 Nov 13;30(17):2617-2624. doi: 10.1097/QAD.0000000000001206. AIDS. 2016. PMID: 27456983 Clinical Trial.
Attitudes to disclosure of HIV-serostatus to new sexual partners and sexual behaviours among HIV-diagnosed gay, bisexual and other men who have sex with men in the UK.
Daskalopoulou M, Rodger AJ, Phillips AN, Gilson R, Sherr L, Wayal S, Anderson J, Aderogba K, McDonnell J, Wilkins E, Youssef E, Speakman A, Burman WJ, Lampe FC. Daskalopoulou M, et al. Among authors: wilkins e. AIDS Care. 2020 Oct;32(10):1323-1332. doi: 10.1080/09540121.2020.1728218. Epub 2020 Mar 1. AIDS Care. 2020. PMID: 32114800
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.
Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. Williams I, et al. Among authors: wilkins e. HIV Med. 2012 Sep;13 Suppl 2:1-85. doi: 10.1111/j.1468-1293.2012.01029.x. HIV Med. 2012. PMID: 22830364 Free article.
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results.
Elion R, Molina JM, Ramón Arribas López J, Cooper D, Maggiolo F, Wilkins E, Conway B, Liu YP, Margot N, Rhee M, Chuck SL, Szwarcberg J; Study 145 Team. Elion R, et al. Among authors: wilkins e. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):494-7. doi: 10.1097/QAI.0b013e318298469c. J Acquir Immune Defic Syndr. 2013. PMID: 23807156 Clinical Trial.
32 results